Open Access

SREBP2 is upregulated in esophageal squamous cell carcinoma and co‑operates with c‑Myc to regulate HMGCR expression

  • Authors:
    • Chenxi Zhong
    • Limin Fan
    • Zhigang Li
    • Feng Yao
    • Heng Zhao
  • View Affiliations

  • Published online on: August 9, 2019     https://doi.org/10.3892/mmr.2019.10577
  • Pages: 3003-3010
  • Copyright: © Zhong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Dysregulations of the mevalonate pathway (MVA) have been previously identified. Our previous study demonstrated that 3‑hydroxy‑3‑methylglutaryl‑coenzyme A reductase (HMGCR), the rate‑limiting enzyme of the MVA pathway, was upregulated in esophageal squamous cell carcinoma (ESCC) and statin‑inhibited ESCC tumorigenesis. However, the underlying mechanism of HMGCR regulation in ESCC remains unknown. In the present study, western blotting and immunohistochemistry analysis demonstrated that sterol regulatory element‑binding protein 2 (SREBP2), the master regulator for HMGCR, was upregulated in ESCC clinical samples. Overexpression of SREBP2 expression in ESCC cell lines promoted the growth, migration and colony formation of cancer cells in the MTT, Boyden chamber and soft agar assays, respectively, which was inhibited by lovastatin. Downregulation of SREBP2 expression in ESCC cell lines inhibited the viability, and migration and colony formation abilities of cancer cells. Assessment of the molecular mechanism demonstrated that SREBP2 interacted with c‑Myc and cooperated with c‑Myc to activate HMGCR expression. Collectively, the present study identified SREBP2 as an oncogene associated with the tumorigenesis of ESCC and further demonstrated the therapeutic effects of statins in ESCC.

References

1 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI

2 

Schwartz L, Supuran CT and Alfarouk KO: The warburg effect and the hallmarks of cancer. Anticancer Agents Med Chem. 17:164–170. 2017. View Article : Google Scholar : PubMed/NCBI

3 

Munkley J and Elliott DJ: Hallmarks of glycosylation in cancer. Oncotarget. 7:35478–35489. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI

5 

Landau BR and Brunengraber H: Shunt pathway of mevalonate metabolism. Methods Enzymol. 110:100–114. 1985. View Article : Google Scholar : PubMed/NCBI

6 

Weinberger C: A model for farnesoid feedback control in the mevalonate pathway. Trends Endocrinol Metab. 7:1–6. 1996. View Article : Google Scholar : PubMed/NCBI

7 

Bathaie SZ, Ashrafi M, Azizian M and Tamanoi F: Mevalonate pathway and human cancers. Curr Mol Pharmacol. 10:77–85. 2017. View Article : Google Scholar : PubMed/NCBI

8 

Swanson KM and Hohl RJ: Anti-cancer therapy: Targeting the mevalonate pathway. Curr Cancer Drug Targets. 6:15–37. 2006. View Article : Google Scholar : PubMed/NCBI

9 

Wang T, Seah S, Loh X, Chan CW, Hartman M, Goh BC and Lee SC: Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget. 7:2532–2544. 2016.PubMed/NCBI

10 

Madison BB: Srebp2: A master regulator of sterol and fatty acid synthesis. J Lipid Res. 57:333–335. 2016. View Article : Google Scholar : PubMed/NCBI

11 

Ma K, Malhotra P, Soni V, Hedroug O, Annaba F, Dudeja A, Shen L, Turner JR, Khramtsova EA, Saksena S, et al: Overactivation of intestinal SREBP2 in mice increases serum cholesterol. PLoS One. 9:e842212014. View Article : Google Scholar : PubMed/NCBI

12 

Shi J, Zhu J, Zhao H, Zhong C, Xu Z and Yao F: Mevalonate pathway is a therapeutic target in esophageal squamous cell carcinoma. Tumour Biol. 34:429–435. 2013. View Article : Google Scholar : PubMed/NCBI

13 

Zhong C, Fan L, Yao F, Shi J, Fang W and Zhao H: HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc. Tumour Biol. 35:4123–4129. 2014. View Article : Google Scholar : PubMed/NCBI

14 

Xie JJ, Xu LY, Wu JY, Shen ZY, Zhao Q, Du ZP, Lv Z, Gu W, Pan F, Xu XE, et al: Involvement of CYR61 and CTGF in the fascin-mediated proliferation and invasiveness of esophageal squamous cell carcinomas cells. Am J Pathol. 176:939–951. 2010. View Article : Google Scholar : PubMed/NCBI

15 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

16 

Mukherjee M, Basu Ball W and Das PK: Leishmania donovani activates SREBP2 to modulate macrophage membrane cholesterol and mitochondrial oxidants for establishment of infection. Int J Biochem Cell Biol. 55:196–208. 2014. View Article : Google Scholar : PubMed/NCBI

17 

Kajinami K, Takekoshi N, Brousseau ME and Schaefer EJ: Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis. 177:219–234. 2004. View Article : Google Scholar : PubMed/NCBI

18 

Caruso MG and Notarnicola M: Biochemical changes of mevalonate pathway in human colorectal cancer. Anticancer Res. 25:3393–3397. 2005.PubMed/NCBI

19 

Andela VB, Pirri M, Schwarz EM, Puzas EJ, O'Keefe RJ, Rosenblatt JD and Rosier RN: The mevalonate synthesis pathway as a therapeutic target in cancer. Clin Orthop Relat Res (415 Suppl). S59–S66. 2003. View Article : Google Scholar

20 

Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al: Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 148:244–258. 2012. View Article : Google Scholar : PubMed/NCBI

21 

Gomes TS, Noguti J, Forones NM, Lima FO, Dobo C, Fernandes Junior JA, Oshima CT and Ribeiro DA: Correlation analysis of c-myc, p21(WAF/CIP1), p53, C-erbB-2 and COX-2 proteins in esophageal squamous cell carcinoma. Pathol Res Pract. 209:6–9. 2013. View Article : Google Scholar : PubMed/NCBI

22 

Brown J, Bothma H, Veale R and Willem P: Genomic imbalances in esophageal carcinoma cell lines involve Wnt pathway genes. World J Gastroenterol. 17:2909–2923. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Wang W, Xue L and Wang P: Prognostic value of β-catenin, c-myc, and cyclin D1 expressions in patients with esophageal squamous cell carcinoma. Med Oncol. 28:163–169. 2011. View Article : Google Scholar : PubMed/NCBI

24 

Ishizuka T, Tanabe C, Sakamoto H, Aoyagi K, Maekawa M, Matsukura N, Tokunaga A, Tajiri T, Yoshida T, Terada M and Sasaki H: Gene amplification profiling of esophageal squamous cell carcinomas by DNA array CGH. Biochem Biophys Res Commun. 296:152–155. 2002. View Article : Google Scholar : PubMed/NCBI

25 

Mandard AM, Hainaut P and Hollstein M: Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res. 462:335–342. 2000. View Article : Google Scholar : PubMed/NCBI

26 

Shukla SK, Gunda V, Abrego J, Haridas D, Mishra A, Souchek J, Chaika NV, Yu F, Sasson AR, Lazenby AJ, et al: MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. Oncotarget. 6:19118–19131. 2015. View Article : Google Scholar : PubMed/NCBI

27 

Miller DM, Thomas SD, Islam A, Muench D and Sedoris K: c-Myc and cancer metabolism. Clin Cancer Res. 18:5546–5553. 2012. View Article : Google Scholar : PubMed/NCBI

28 

Gordan JD, Thompson CB and Simon MC: HIF and c-Myc: Sibling rivals for control of cancer cell metabolism and proliferation. Cancer cell. 12:108–113. 2007. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 20 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhong, C., Fan, L., Li, Z., Yao, F., & Zhao, H. (2019). SREBP2 is upregulated in esophageal squamous cell carcinoma and co‑operates with c‑Myc to regulate HMGCR expression. Molecular Medicine Reports, 20, 3003-3010. https://doi.org/10.3892/mmr.2019.10577
MLA
Zhong, C., Fan, L., Li, Z., Yao, F., Zhao, H."SREBP2 is upregulated in esophageal squamous cell carcinoma and co‑operates with c‑Myc to regulate HMGCR expression". Molecular Medicine Reports 20.4 (2019): 3003-3010.
Chicago
Zhong, C., Fan, L., Li, Z., Yao, F., Zhao, H."SREBP2 is upregulated in esophageal squamous cell carcinoma and co‑operates with c‑Myc to regulate HMGCR expression". Molecular Medicine Reports 20, no. 4 (2019): 3003-3010. https://doi.org/10.3892/mmr.2019.10577